Related references
Note: Only part of the references are listed.Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.
D. Weiser et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.
R. L. Ladenstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants A Children's Oncology Group Study
Jed G. Nuchtern et al.
ANNALS OF SURGERY (2012)
Replication of Neuroblastoma SNP Association at the BARD1 Locus in African-Americans
Valeria Latorre et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity
Kristopher R. Bosse et al.
CANCER RESEARCH (2012)
Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
Yael P. Mosse et al.
CLINICAL CANCER RESEARCH (2012)
Mechanisms of CHD5 Inactivation in Neuroblastomas
Hiroshi Koyama et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Steven G. DuBois et al.
CLINICAL CANCER RESEARCH (2012)
Promising Therapeutic Targets in Neuroblastoma
Katherine K. Matthay et al.
CLINICAL CANCER RESEARCH (2012)
Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets
Elizabeth R. Lawlor et al.
CLINICAL CANCER RESEARCH (2012)
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
G. J. Veal et al.
EUROPEAN JOURNAL OF CANCER (2012)
Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Nai-Kong V. Cheung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Shahab Asgharzadeh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641
Douglas R. Strother et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Jan J. Molenaar et al.
NATURE (2012)
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma
Sharon J. Diskin et al.
NATURE GENETICS (2012)
Epigenetic protein families: a new frontier for drug discovery
Cheryl H. Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma (vol 31, pg 4859, 2012)
E. L. Carpenter et al.
ONCOGENE (2012)
Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma
Yvan H. Chanthery et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
G. Schleiermacher et al.
BRITISH JOURNAL OF CANCER (2011)
CAMTA1, a 1p36 Tumor Suppressor Candidate, Inhibits Growth and Activates Differentiation Programs in Neuroblastoma Cells
Kai-Oliver Henrich et al.
CANCER RESEARCH (2011)
Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors
Sheri L. Spunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: A Children's Oncology Group Study
Tara O. Henderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma Without MYCN Amplification: Results of the Prospective INES 99.1
Herve Rubie et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study
Rochelle Bagatell et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrative genomics identifies LMO1 as a neuroblastoma oncogene
Kai Wang et al.
NATURE (2011)
CASZ1b, the Short Isoform of CASZ1 Gene, Coexpresses with CASZ1a during Neurogenesis and Suppresses Neuroblastoma Cell Growth
Zhihui Liu et al.
PLOS ONE (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Scott C. Bresler et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci
Le B. Nguyen et al.
PLOS GENETICS (2011)
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
Christa E. Nath et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Global genomic and RNA profiles for novel risk stratification of neuroblastoma
Miki Ohira et al.
CANCER SCIENCE (2010)
Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature
Katleen De Preter et al.
CLINICAL CANCER RESEARCH (2010)
Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
Suzanne Shusterman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Impact of Gene Expression-Based Classification for Neuroblastoma
Andre Oberthuer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Accumulation of Segmental Alterations Determines Progression in Neuroblastoma
Gudrun Schleiermacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
Peter J. Houghton et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma.
David L. Baker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Medical Progress: Recent Advances in Neuroblastoma.
John M. Maris
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical Outcome in Children With Recurrent Neuroblastoma Treated With ABT-751 and Effect of ABT-751 on Proliferation of Neuroblastoma Cell Lines and on Tubulin Polymerization In Vitro
Holly J. Meany et al.
PEDIATRIC BLOOD & CANCER (2010)
Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force
K. Beiske et al.
BRITISH JOURNAL OF CANCER (2009)
Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
Tobias Otto et al.
CANCER CELL (2009)
Targeting Ornithine Decarboxylase Impairs Development of MYCN-Amplified Neuroblastoma
Robert J. Rounbehler et al.
CANCER RESEARCH (2009)
Busulfan in hematopoietic stem cell transplant setting
Jeannine S. McCune et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
Isabelle Janoueix-Lerosey et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Tom Monclair et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Susan L. Cohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Copy number variation at 1q21.1 associated with neuroblastoma
Sharon J. Diskin et al.
NATURE (2009)
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma
Mario Capasso et al.
NATURE GENETICS (2009)
Transcriptional adaptation of neuroblastoma cells to hypoxia
Erik Fredlund et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group
B. De Bernardi et al.
BRITISH JOURNAL OF CANCER (2008)
ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma
Michael D. Hogarty et al.
CANCER RESEARCH (2008)
The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastorna >1 year of age on a high-risk treatment protocol:: Results of the German Neuroblastoma Trial NB97
Matthias Schmidt et al.
EUROPEAN JOURNAL OF CANCER (2008)
A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study
S. G. Kreissman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Localized infant neuroblastomas often show spontaneous regression: Results of the prospective trials NB95-S and NB97
Barbara Hero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas
Tomoyuki Fujita et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Screening for neuroblastoma: a resurrected idea?
John M. Maris et al.
LANCET (2008)
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial
Andrew D. J. Pearson et al.
LANCET ONCOLOGY (2008)
Identification of ALK as a major familial neuroblastoma predisposition gene
Yael P. Mosse et al.
NATURE (2008)
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma
John M. Maris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
Frank Westermann et al.
GENOME BIOLOGY (2008)
Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo
J. I. Johnsen et al.
ONCOGENE (2008)
Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification
X. Liu et al.
ONCOGENE (2008)
Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors
J. Bouligand et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma
Christina M. Coughlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
Julia A. Messina et al.
PEDIATRIC BLOOD & CANCER (2006)
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
Brian H. Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Chronic health conditions in adult survivors of childhood cancer
Kevin C. Oeffinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification
Shahab Asgharzadeh et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q
T Simon et al.
CANCER LETTERS (2006)
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group
KL Osenga et al.
CLINICAL CANCER RESEARCH (2006)
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study
KK Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Chromosome 1p and 11q deletions and outcome in neuroblastoma
EF Attiyeh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Surgical risk factors in primary surgery for localized neuroblastoma:: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group
G Cecchetto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
[131I]meta-ldobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter
AG McCluskey et al.
CLINICAL CANCER RESEARCH (2005)
Design issues of randomized phase II trials and a proposal for phase II screening trials
LV Rubinstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group
WB London et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial
F Berthold et al.
LANCET ONCOLOGY (2005)
Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma
MN Gaze et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study
T Oue et al.
JOURNAL OF PEDIATRIC SURGERY (2005)
Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity
J Zwaveling et al.
BONE MARROW TRANSPLANTATION (2005)
Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma
SM Bradfield et al.
CANCER (2004)
Germline PHOX2B mutation in hereditary neuroblastoma
YP Mosse et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
KK Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Early selection in a randomized phase II clinical trial
SM Steinberg et al.
STATISTICS IN MEDICINE (2002)
Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma
GA Yanik et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Neuroblastoma screening at one year of age
FH Schilling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Retinoid therapy of childhood cancer
CP Reynolds et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2001)
Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization:: A pediatric oncology group study
P Mathew et al.
NEOPLASIA (2001)
High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma
A Islam et al.
ONCOGENE (2000)
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study
HJ Nickerson et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
